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Abstract
Background: Objective of this study was to make an assessment of standard functional and defor-
mation parameters (strain) in patients after transcatheter aortic valve replacement (TAVR) by cardiac 
magnetic resonance imaging (CMR) and the evaluation of their prognostic impact.
Methods: Patients undergoing TAVR received CMR on a 1.5 T whole-body scanner at 3 months after 
the procedure. Deformation parameters (strain, strain rate, velocity, displacement) were assessed in lon-
gitudinal, circumferential and radial orientation using a feature tracking approach. Primary outcome 
measure was defined according to Valve Academic Research Consortium-2 (VARC-2) criteria. 
Results: Eighty-three patients formed the study population. Deformation parameters were significantly 
reduced in all three orientations for strain (longitudinal: –12.1 ± 5.4% vs. –15.9 ± 1.96%, p < 0.0001; 
radial: 34.4 ± 15.3% vs. 47.2 ± 11.4%, p < 0.0001; circumferential: –16.8 ± 4.3% vs. –21.1 ± 2.5%, 
p < 0.0001) and strain rate (longitudinal: –0.79 ± 0.33%/s vs. –0.91 ± 0.23%/s, p = 0.043; radial: 
2.5 ± 1.2%/s vs. 2.9 ± 0.9%, p = 0.067; circumferential: –1.1 ± 0.6%/s vs. –1.3 ± 0.3%/s, p = 0.006) 
in comparison to a healthy control population. Median follow-up was 614 days. During this period, 
13 endpoints occurred (cumulative event rate of 10.7%). Patients with event by trend exhibited poorer 
strain and strain rate in longitudinal and radial orientation without reaching statistical significance 
(longitudinal strain: –11.2 ± 5.4% vs. –12.3 ± 5.4%, p = 0.52; longitudinal strain rate: –0.73 ±  
± 0.23%/s vs. 0.80 ± 0.35%/s, p = 0.53; radial strain: 29.5 ± 19.6% vs. 35.2 ± 14.5%, p = 0.24; 
radial strain rate: 2.2 ± 1.6%/s vs. 2.6 ± 1.2%/s, p = 0.31).  
Conclusions: Assessment of left ventricular deformation parameters by CMR revealed functional 
abnormalities in comparison to healthy controls. Prognostic significance remains to be further investi-
gated. (Cardiol J 2018; 25, 2: 203–212)
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Introduction
Aortic stenosis (AS) is the most common 
valvular pathology in western populations, es-
pecially in the elderly [1]. Indication for aortic 
valve replacement in patients with severe AS is 
given as soon as typical symptoms occur [2]. In 
patients at intermediate to high surgical risk, 
transcatheter aortic valve replacement (TAVR) 
has been shown to be superior to surgical valve 
replacement [3–5]. 
Several factors such as need for hemodynamic 
support during procedure, extent of paravalvular 
leakage, chronic kidney or pulmonary disease 
have been identified to influence early and mid-
term prognosis after TAVR [6, 7]. However most 
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studies forming the evidence base concentrate 
on acute outcomes. Hence there is little data on 
outcomes beyond the first year of follow-up [8, 9]. 
Valid prognostic information is of special interest 
as it might provide important contributions to risk 
stratification and clinical decision making espe-
cially in the context of present ongoing randomized 
trials in patients with a low risk for surgical valve 
replacement. 
Cardiac magnetic resonance imaging (CMR) 
plays an increasing role in the diagnostic manage-
ment of patients suffering from valvular pathologies 
[10]. In addition to its favorable advantages like 
high spatial and temporal resolution, lack of ion-
izing radiation and excellent reproducibility, it is 
considered the gold standard for the evaluation and 
quantification of left and right ventricular functional 
parameters such as volumes and ejection fractions 
[11]. Consequently, CMR has proven to provide im-
portant prognostic information in various valvular 
and non-valvular cardiac diseases [12–14]. Most 
recently, new parameters for the quantification of 
left ventricular mechanics and function have been 
introduced to CMR. The assessment of global and 
regional strain and subsequent parameters such as 
strain rate, displacement and velocity by feature 
tracking (FT) CMR is thought to have the potential 
to improve the quantification of cardiac function 
and thus might lead to an improvement of CMR’s 
prognostic value [15–19]. 
The objective of this study was to make an 
assessment of standard functional and innovative 
deformation parameters in patients after TAVR by 
CMR and the evaluation of their prognostic impact.
Methods
Study population
Patients with symptomatic severe AS un-
dergoing TAVR were enrolled between 2014 and 
2015. Indication for valve replacement was given 
according to current guidelines [20]. All patients 
were considered eligible unless they exhibited 
predefined exclusion criteria such as cardiac or 
respiratory instability, metal implants or devices 
unsuitable for CMR, concomitant limiting disease, 
allergy against gadolinium based contrast agents 
or severely impaired renal function. Age and sex 
were matched with a healthy control population 
and was derived from a database formed within 
another project which was conducted for estab-
lishment of reference values. For these subjects, 
any form of relevant valvular or coronary artery 
disease, hypertrophic or dilative cardiomyopathy, 
diastolic dysfunction or inflammatory heart disease 
were ruled out. 
The study was approved by the institutional eth-
ics committee (clinicaltrials.gov: NCT02162069). 
Written informed consent was obtained from every 
patient as well as from healthy controls.
CMR examination
All patients received CMR examination at 
3 months after TAVR. CMR imaging was performed 
on a 1.5 T whole-body clinical magnetic resonance 
scanner (Achieva 1.5T, Philips Medical Systems, 
Best, Netherlands) using a 32-channel phased-ar-
ray receiver coil. CMR examinations were carried 
out in concordance with current guidelines [21, 22]. 
A steady-state free precession sequence (SSFP, 
repetition time 3.4 ms, echo time 1.7 ms, voxel 
size 1.6 × 1.6 mm, flip-angle a 55°, slice thickness 
8 mm, acquisition in end-expiratory breath-hold, 
32 cardiac phases) were used for functional imaging 
of the left and right ventricle in long and short axis 
orientation. CMR examinations and FT analyzes 
were performed identically for AS patients and 
healthy controls.
CMR analysis
Two experienced readers performed offline 
image analysis in a consensus approach. Epi- and 
endocardial contours were drawn manually in the 
long- and short-axis oriented SSFP-images. Ba-
sic functional (left and right ventricular ejection 
fraction [LVEF, RVEF], left and right ventricular 
end-diastolic volume index [LVEDI, RVEDVI], 
left ventricular mass/volume index [LVMVI], left-
ventricular mass divided by left-ventricular end-
diastolic volume) and strain parameters (strain, 
systolic strain rate, displacement, systolic velocity) 
were derived from the SSFP cine images using 
the dedicated software cvi42® (Version 5.2, Circle 
Cardiovascular Imaging, Calgary, Canada). Strain 
parameters in longitudinal and radial orientation 
were assessed globally and on a segmental basis for 
the left ventricle according to current recommen-
dations [23]. Global circumferential function was 
derived from a mid-ventricular slice and expressed 
as positive number in case of a clockwise rotation 
(seen from the apex) or as a negative number in 
case of a counterclockwise movement (example 
depicted in Figure 1). 
Follow-up
Patients had a follow-up after 3, 6, 12 and 
24 months after TAVR. Primary outcome meas-
ure was defined according to the Valve Academic 
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Research Consortium-2 (VARC-2) criteria. The 
composite endpoint death of any cause, non-fatal 
myocardial infarction, hospitalization due to heart 
failure and cerebral ischemia (not associated to index 
procedure, after hospital discharge) [24] was ana-
lyzed. Non-fatal myocardial infarction was defined 
according to the current universal definition [25].
Statistical analysis
To test the correlation between two categori-
cal classification factors, the c2 test was applied. 
Continuous variables were tested for normal dis-
tribution by the D’Agostino-Pearson test. Variables 
with normal distribution were reported as mean 
± standard deviation and a two-tailed t-test (for 
independent samples) was used for comparison. 
Variables without normal distribution were re-
ported as median with percentiles and compared 
by the Mann-Whitney-U rank sum test. Univari-
ate regression analyses using Cox’s proportional 
hazard models were performed to estimate the 
predictive value of the variables. Hazard ratio (HR) 
and corresponding 95% confidence interval (CI) 
are provided. A p-value < 0.05 was considered sig-
nificant. Statistical analyses were performed using 
commercially available software (Stata 13, College 
Station, USA, MedCalc, Mariakerke, Belgium).
Results
Study population and functional  
characteristics before TAVR
Eighty-three patients after TAVR for treat-
ment of symptomatic severe AS were enrolled 
into the study. Mean age was 79.3 ± 5.6 years. 
Forty-three patients were men (51.8%). Most of 
the patients presented in functional New York 
Heart Association (NYHA) class III or IV (n = 72, 
Figure 1. Example of deformation parameter assessment. Endocardial (red lining) and epicardial (green lining) in long 
axis (A) and short axis (B) orientation. Movement and deformation of strain vectors can be seen. A three-dimensional 
model is calculated based on two-dimensional information (C) and results are depicted in a 16-segments bulls-eye 
plot (here for radial strain, D).
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86.8%). Mean EuroSCORE II was 5.0 ± 3.6% 
[26], Society of Thoracic Surgeons (STS) score 
for mortality was 5.5 ± 3.7% [27]. Table 1 depicts 
clinical baseline characteristics including relevant 
pre-existing conditions and functional characteris-
tics before TAVR in more detail. 
Mean LVEF was 57.6 ± 15.7% before TAVR in 
echocardiography. Ten patients exhibited a LVEF 
< 35% (12.0%) and 43 (51.8%) patients had pul-
monary hypertension. More than moderate mitral 
and tricuspid valve regurgitation was found in 18 
(22.5%) and 13 (16.4%) cases, respectively. 
CMR assessment of basic functional and 
left ventricular deformation parameters 
Three months after TAVR, LVEF as assessed 
by CMR was a mean 61.1 ± 14.0%. A severely 
impaired LVEF (LVEF < 35%) was present in 
5 (6.0%) patients. In comparison to the control 
group with a mean LVEF of 68.4 ± 5.4%, the LVEF 
in the TAVR population was significantly lower 
(p = 0.002). LVEDVI was significantly higher in 
the TAVR cohort (78.9 ± 23.2 mL/m2 vs. 65.2 ± 
± 16.5 mL/m2, p = 0.001) as well as LVMVI 
(0.86 ± 0.28 g/mL vs. 0.70 ± 0.08 g/mL, p = 0.001). 
Right ventricular parameters did not statistically 
differ as detailed in Table 2.
Deformation analysis by FT CMR yielded sig-
nificantly reduced results in all three orientations 
for strain (longitudinal: –12.1 ± 5.4% vs. –15.9 ± 
± 1.96%, p < 0.0001; radial: 34.4 ± 15.3% vs. 47.2 ± 
± 11.4%, p < 0.0001; circumferential: –16.8 ± 4.3% 
vs. –21.1 ± 2.5%, p < 0.0001). In addition the strain 
rate in the TAVR population was significantly re-
duced compared to the control group (longitudinal: 
–0.79 ± 0.33%/s vs. –0.91 ± 0.23%/s, p = 0.043; 
radial: 2.5 ± 1.2%/s vs. 2.9 ± 0.9%, p = 0.067; 
circumferential: –1.1 ± 0.6%/s vs. –1.3 ± 0.3%/s, 
p = 0.006). Global peak displacement and global 
peak velocity in radial orientation were also signifi-
cantly reduced in the TAVR population compared 
with the control population (displacement: 5.1 ± 
± 2.0 mm vs. 6.8 ± 0.87 mm, p < 0.0001; velocity: 
33.1 ± 11.9 mm/s vs. 40.7 ± 8.6 mm/s, p < 0.001). 
In addition, direction of global circumferential 
strain (clockwise vs. counterclockwise) signifi-
cantly differed between the TAVR cohort and the 
control group (2.9 ± 5.2 deg vs. –0.5 ± 5.4 deg).
Follow-up
Median follow-up was 614 days with 61 (73.5%) 
patients having 12 months follow-up. Thirty-five 
(42.2%) patients had a follow-up period of more 
than 2 years. During the follow-up period, 
13 endpoints occurred. Five (6.0%) patients died. 
Two patients had non-fatal myocardial infarctions 
(2.4%) and 3 (3.6%) patients had to be hospital-
ized because of heart failure. Cerebral ischemia 
occurred in 2 (2.4%) subjects. Cumulative event 
rate was 10.7%.
Predictors of outcomes
Table 3 depicts characteristics of patients with 
vs. without event. There is no significant difference 
with regard to basic clinical features such as age, 
sex, diabetes or hypertension. Established risk 
prediction parameters (NYHA class at 3 months 
follow-up, frailty, STS score and EuroSCORE II) 
also showed comparable results for both groups. 
The frequency of cardiac and non-cardiac comorbid-
ities (presence of coronary artery disease, chronic 
obstructive lung disease, pulmonary hypertension, 
severe mitral or tricuspid valve regurgitation, 
paravalvular leakage > 1) was also not significantly 
different. Patients with event exhibited poorer left 
and right ventricular functional parameters without 
reaching statistical significance (LVEF: 57.3 ± 
± 11.4% vs. 61.7 ± 14.4%, p = 0.32; LVEDVI: 
Table 1. Baseline characteristics.
Variable N = 83
Age [years] 79.3 ± 5.6
Body mass index [kg/m2] 27.7 ± 4.7
Male 43 (51.8%)
Diabetes mellitus 26 (31.3%)
Arterial hypertension 78 (94.0%)
NYHA functional class (baseline):
II 11 (13.2%)
III–IV 72 (86.8%)
Frailty 43 (51.8%)
STS score [%] — mortality 5.5 ± 3.7
EuroSCORE II [%] 5.0 ± 3.6
Atrial fibrillation 29 (34.9%)
Coronary artery disease 49 (59.0%)
Cerebrovascular disease 7 (8.4%)
Chronic obstructive pulmonary disease 9 (10.8%)
eGFR > 60 mL/min 48 (57.8%)
Functional characteristics before TAVR
LVEF [%] 57.6 ± 15.7
Aortic valve area [cm2] 0.76 ± 0.24
Max PG [mm Hg] 64.9 ± 22.7
Values are mean ± standard deviation or n (%); eGFR — estimated 
glomerular filtration rate; LVEF — left ventricular ejection fraction; 
Max PG — maximal pressure gradient; NYHA — New York Heart 
Association; STS — Society of Thoracic Surgeons; TAVR — trans-
catheter aortic valve replacement
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Table 2. Comparison of functional and deformation parameters of study cohort after transcatheter  
aortic valve replacement (TAVR) and control group.
Variable TAVR cohort (n = 83) Control group (n = 39) P
LVEF [%] 61.1 ± 14.0 68.4 ± 5.4 < 0.002
LVEDVI [mL/m2] 78.9 ± 23.2 65.2 ± 16.5 < 0.001
LVMVI [g/mL] 0.86 ± 0.28 0.70 ± 0.08 < 0.001
RVEF [%] 61.7 ± 12.6 65.4 ± 8.0 0.10
RVEF < 35 2 (2.4%) 0 (0%) 0.09
RVEDVI [mL/m2] 69.7 ± 17.3 66.1 ± 17.7 0.29
Global longitudinal:
Peak strain [%] –12.1 ± 5.4 –15.9 ± 1.96 < 0.0001
Peak strain rate [%/s] –0.79 ± 0.33 –0.91 ± 0.23 0.043
Peak displacement [mm] 3.9 ± 2.1 3.3 ± 1.3 0.10
Peak velocity [mm/s] 39.8 ± 16.5 42.0 ± 12.4 0.46
Global radial:
Peak strain [%] 34.4 ± 15.3 47.2 ± 11.4 < 0.0001
Peak strain rate [%/s] 2.5 ± 1.2 2.9 ± 0.9 0.07
Peak displacement [mm] 5.1 ± 2.0 6.8 ± 0.87 < 0.0001
Peak velocity [mm/s] 33.1 ± 11.9 40.7 ± 8.6 < 0.001
Mid-ventricular circumferential:
Peak strain [%] –16.8 ± 4.3 –21.1 ± 2.5 < 0.0001
Peak strain rate [%/s] –1.1 ± 0.4 –1.3 ± 0.3 < 0.006
Peak displacement [deg] 2.9 ± 5.2 –0.5 ± 5.4 < 0.001
Peak velocity [deg/s] 36.0 ± 63.3 24.4 ± 70.2 0.36
Values are mean ± standard deviation or n (%). LVEDVI — left ventricular end-diastolic volume index; LVEF — left ventricular ejection fraction; 
LVMVI — left ventricular mass/volume index; RVEDVI — right ventricular end-diastolic volume index; RVEF — right ventricular ejection fraction
83.5 ± 22.7 mL/m2 vs. 78.1 ± 23.3 mL/m2, p = 0.46; 
LVMVI: 0.83 ± 0.3 g/mL vs. 0.86 ± 0.3 g/mL, 
p = 0.75; RVEF: 56.9 ± 10.8% vs. 62.6 ± 12.7%, 
p = 0.15; RVEDVI: 74.6 ± 24.8 mL/m2 vs. 68.8 ± 
± 15.7 mL/m2, p = 0.28). Peak strain and peak 
strain rate in longitudinal and radial orientation 
tended to be reduced, mid-ventricular circumferen-
tial strain did not differ (longitudinal strain: –11.2 ± 
± 5.4% vs. –12.3 ± 5.4%, p = 0.52; longitudinal 
strain rate: –0.73 ± 0.23%/s vs. 0.80 ± 0.35%/s, 
p = 0.53; radial strain: 29.5 ± 19.6% vs. 35.2 ± 
± 14.5%, p = 0.24; radial strain rate: 2.2 ± 1.6%/s 
vs. 2.6 ± 1.2%/s, p = 0.31). 
Table 4 compares patients after TAVR without 
endpoint and healthy controls. Global peak strain 
was reduced in all orientations (longitudinal: 
–12.3 ± 5.4% vs. –15.9 ± 2.0, p < 0.0001; ra-
dial: 35.2 ± 14.5% vs. 47.2 ± 11.4%, p < 0.0001; 
mid-ventricular circumferential: –16.8 ± 4.5% vs. 
–21.1 ± 2.5%, p < 0.0001).
In Table 5, analyses of univariate predictors 
of endpoints are shown. NYHA functional class 
3 months after TAVR was the only parameter 
with significant correlation to event-free survival. 
Patients persisting in NYHA class III or IV ex-
hibited a HR of 6.69 (p = 0.02). Clinical features, 
risk prediction models, comorbidities and CMR 
parameters were not significantly associated with 
the occurrence of endpoints. 
Discussion
The present study evaluates cardiac defor-
mation characteristics of patients 3 months after 
TAVR and analyzes their correlation to event-free 
survival in a 2 year follow-up. The main finding 
is that left-ventricular deformation parameters 
(strain, strain rate, displacement and velocity) in 
longitudinal, radial and circumferential orientation 
were significantly reduced 3 months after success-
ful TAVR in comparison to a healthy control group. 
This was also true for patients with preserved 
ejection fraction. Patients with endpoint tended 
to exhibit lower strain values in comparison to pa-
tients without event, though statistical significance 
was not reached. Despite having higher values by 
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trend, deformation characteristics of AS patients 
without event still were significantly reduced in 
comparison to normal controls.
Strain imaging is an emerging technique for 
the non-invasive evaluation of global and regional 
left ventricular function [28]. Thus far, most studies 
addressing this topic are derived from two-dimen-
sional speckle-tracking echocardiography. There 
are various studies proving prognostic significance 
of particular speckle-tracking derived strain param-
eters, foremost being global longitudinal strain. 
This parameter has proven to be significantly 
correlated to adverse events in several settings, 
from heart transplant patients to severe AS [29, 
30]. Though this technique is highly accepted and 
widely available, it exhibits several inherent limita-
tions such as poor inter-reader reproducibility and 
need for an appropriate ‘acoustic window’ [31, 32]. 
FT CMR offers the possibility to derive deformation 
parameters from standard cine sequences and thus 
combines the advantages of both imaging modalities 
[15, 16]. CMR derived left-ventricular strain was an 
independent predictor of survival in patients with 
dilated cardiomyopathy [33]. Moreover, it proved 
to provide significant prognostic power concerning 
the occurrence of major adverse cardiac events in 
an all-comers CMR population [34].
The findings of the present study are in con-
cordance with an earlier study using speckle track-
ing echocardiography for the assessment of cardiac 
mechanics in AS patients before and after surgical 
valve replacement [35]. Patients in this study 
exhibited significantly lower values for longitudi-
nal (–14.6 ± 4.1% vs. –20.3 ± 2.3%, p < 0.001), 
radial (33.1 ± 14.8% vs. 38.9 ± 6.4%, p < 0.001) 
and circumferential strain (–15.2 ± 5.0% vs. 
–19.5 ± 2.9%, p < 0.001) before TAVR in com-
parison to normal controls, despite normal LVEF 
(60 ± 12%). It could be demonstrated that valve 
replacement lead to an improvement in cardiac 
function (longitudinal strain: from –14.6 ± 4.1% to 
–16.4 ± 4.5%, p < 0.001; radial strain: from 33.1 ± 
± 14.8% to 37.2 ± 13.4%, p = 0.02; circumfer-
ential strain: from –15.2 ± 5.0% to –18.0 ± 5.3%, 
p < 0.001) but that deformation parameters still 
were reduced in comparison to healthy controls, 
especially in longitudinal direction (–16.9 ± 4.8% 
vs. –20.3 ± 2.3%, p < 0.0001). 
A recent study proved the strong correlation 
between CMR derived deformation parameters and 
Table 3. Comparison of patients with versus without event.
Variable Event (n = 12) No event (n = 71) P
LVEF [%] 57.3 ± 11.4 61.7 ± 14.4 0.32
LVEDVI [mL/m2] 83.5 ± 22.7 78.1 ± 23.3 0.46
LVMVI [g/mL] 0.83 ± 0.3 0.86 ± 0.3 0.75
RVEF [%] 56.9 ± 10.8 62.6 ± 12.7 0.15
RVEDVI [mL/m2] 74.6 ± 24.8 68.8 ± 15.7 0.28
Global longitudinal:
Peak strain [%] –11.2 ± 5.4 –12.3 ± 5.4 0.52
Peak strain rate [%/s] –0.74 ± 0.23 –0.80 ± 0.35 0.53
Peak displacement [mm] 3.9 ± 2.3 3.9 ± 2.1 1.00
Peak velocity [mm/s] 38.7 ± 17.8 40.0 ± 16.4 0.80
Global radial:
Peak strain [%] 29.5 ± 19.6 35.2 ± 14.5 0.24
Peak strain rate [%/s] 2.2 ± 1.6 2.6 ± 1.2 0.31
Peak displacement [mm] 4.8 ± 2.6 5.2 ± 1.9 0.53
Peak velocity [mm/s] 34.0 ± 9.6 33.0 ± 12.3 0.79
Mid-ventricular circumferential:
Peak strain [%] –16.8 ± 2.7 –16.8 ± 4.5 1.00
Peak strain rate [%/s] –1.1 ± 0.4 –1.1 ± 0.3 1.00
Peak displacement [deg] 1.1 ± 4.2 3.2 ± 5.3 0.20
Peak velocity [deg/s] 44.4 ± 63.6 34.5 ± 64.3 0.62
Values are mean ± standard deviation; LVEDVI — left ventricular end-diastolic volume index; LVEF — left ventricular ejection fraction;  
LVMVI — left ventricular mass/volume index; RVEDVI — right ventricular end-diastolic volume index; RVEF — right ventricular ejection fraction
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the underlying hemodynamic AS subtype [36].  As 
it could be demonstrated that positive response 
after TAVR could be predicted by analysis of lon-
gitudinal strain and velocity, it has been suggested 
that the evaluation of cardiac mechanics could be 
useful for the right timing of valve replacement. 
Nevertheless, prognostic implication of persisting 
subtle functional abnormalities after TAVR remain 
poorly investigated and are thus unclear [37]. 
A correlation of deformation parameters to outcomes 
have not as yet been reported.
Many studies report that early events in the 
first few weeks after TAVR are mainly related 
to the procedure itself including major vascular 
complications, bleeding complications, cerebral 
infarction or severe paravalvular aortic insuffi-
ciency [6, 9]. Our cohort consisted of patients with 
a follow-up CMR 3 months after successful aortic 
valve replacement. Therefore, early events within 
the first few weeks after TAVR were excluded from 
analyses. Though this approach might introduce 
a certain selection bias, it could be appropriate for 
the proper identification of predictors of mid- and 
long-term outcomes after interventional valve 
replacement. Hence, patients surviving 3 months 
after TAVR had an excellent prognosis and exhib-
ited only relatively low event rates. 
Several observational and register studies 
sought to identify factors predicting outcomes in 
patients after TAVR [9, 38, 39]. It is of note that most 
of these studies reported non-cardiac morbidities 
being causative for deaths and rehospitalizations 
during follow-up > 30 days after valve replacement. 
Interestingly, in all of the studies addressing this is-
sue, left ventricular functional parameters such as 
LVEF and LVEDVI did not have statistical impact 
on outcomes after valve replacement, indicating 
that non-cardiac conditions gain influence after 
successful treatment of AS. In concordance to this 
assumption, a strong correlation of NYHA functional 
class after TAVR and the occurrence of endpoints 
could be observed in the present study.
Nevertheless, since indication for TAVR is 
constantly expanding toward patients at low to 
intermediate risk, it can be assumed that functional 
cardiac parameters will show greater prognostic 
power in this population exhibiting lower frequen-
cies of severe comorbidities [40]. Several studies 
have suggested that the evaluation of deformation 
characteristics might provide beneficial additive 
Table 4. Comparison of patients without event and controls.
Variable No event (n = 71) Control group (n = 39) P
LVEF [%] 61.7 ± 14.4 68.4 ± 5.4 < 0.006
LVEDVI [mL/m2] 78.1 ± 23.3 65.2 ± 16.5 < 0.003
LVMVI [g/mL] 0.86 ± 0.3 0.70 ± 0.08 < 0.002
RVEF [%] 62.6 ± 12.7 65.4 ± 8.0 0.22
RVEDVI [mL/m2] 68.8 ± 15.7 66.1 ± 17.7 0.41
Global longitudinal:
Peak strain [%] –12.3 ± 5.4 –15.9 ± 2.0 < 0.0001
Peak strain rate [%/s] –0.80 ± 0.35 –0.91 ± 0.23 0.08
Peak displacement [mm] 3.9 ± 2.1 3.3 ± 1.3 0.11
Peak velocity [mm/s] 40.0 ± 16.4 42.0 ± 12.4 0.51
Global radial:
Peak strain [%] 35.2 ± 14.5 47.2 ± 11.4 < 0.0001
Peak strain rate [%/s] 2.6 ± 1.2 2.9 ± 0.9 0.18
Peak displacement [mm] 5.2 ± 1.9 6.8 ± 0.87 < 0.0001
Peak velocity [mm/s] 33.0 ± 12.3 40.7 ± 8.6 < 0.001
Mid-ventricular circumferential:
Peak strain [%] –16.8 ± 4.5 –21.1 ± 2.5 < 0.0001
Peak strain rate [%/s] –1.1 ± 0.3 –1.3 ± 0.3 < 0.001
Peak displacement [deg] 3.2 ± 5.3 –0.5 ± 5.4 < 0.001
Peak velocity [deg/s] 34.5 ± 64.3 24.4 ± 70.2 0.45
Values are mean ± standard deviation; LVEDVI — left ventricular end-diastolic volume index; LVEF — left ventricular ejection fraction;  
LVMVI — left ventricular mass/volume index; RVEDVI — right ventricular end-diastolic volume index; RVEF — right ventricular ejection fraction
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information over the assessment of basic functional 
parameters alone [15, 16]. 
In the present study, a significant association 
of deformation parameters and poor outcome could 
not be proven. However, patients with endpoint had 
lower strain values by trend than patients without 
endpoint. It can be assumed that the investigated 
parameters will gain significance in larger AS 
cohorts and longer follow-up periods, particularly 
in low-risk AS populations. Thus, evaluation of 
deformation and mechanical characteristics by 
CMR seem to be a promising approach to improve 
understanding of cardiac functional properties and 
the prognostic implications linked to them.
Table 5. Univariate predictors of composite endpoint.
Variable Hazard ratio 95% CI P
Age [per year] 1.01 0.91–1.12 0.83
Body mass index [per kg/m2] 0.99 0.88–1.13 0.93
Male 3.36 0.90–12.47 0.07
Diabetes mellitus 0.65 0.18–2.42 0.52
Arterial hypertension 0.52 0.07–4.08 0.53
NYHA functional class (follow-up) III–IV 6.69 1.38–32.36 0.02
Frailty 0.88 0.28–2.84 0.84
STS score (%) — mortality 1.01 0.86–1.17 0.95
EuroSCORE II [%] 1.05 0.91–1.21 0.50
Atrial fibrillation 1.31 0.39–4.35 0.66
Coronary artery disease 0.26 0.06–1.21 0.09
Chronic obstructive pulmonary disease 2.65 0.71–9.82 0.15
Systolic pulmonary artery pressure:
31–55 mm Hg 1.15 0.37–3.59 0.81
> 55 mm Hg 1.27 0.33–4.85 0.73
Paravalvular leak > 1 1.12 0.33–3.85 0.86
LVEF [%] 0.98 0.94–1.02 0.29
LVEDVI [mL/m2] 1.01 0.99–1.03 0.37
LVMVI [g/mL] 1.42 0.15–13.15 0.76
RVEF [%] 0.98 0.95–1.01 0.20
RVEDVI [mL/m2] 1.01 0.98–1.05 0.39
Global longitudinal:
Peak strain [%] 1.05 0.94–1.16 0.41
Peak strain rate [%/s] 0.99 0.97–1.01 0.40
Peak displacement [mm] 0.97 0.75–1.32 0.97
Peak velocity [mm/s] 0.74 0.96–1.03 0.74
Global radial:
Peak strain [%] 0.98 0.95–1.01 0.22
Peak strain rate [%/s] 1.00 0.99–1.00 0.24
Peak displacement [mm] 0.94 0.72–1.23 0.67
Peak velocity [mm/s] 1.01 0.96–1.06 0.82
Mid-ventricular circumferential:
Peak strain [%] 1.00 0.80–1.26 0.98
Peak strain rate [%/s] 0.94 0.08–10.96 0.96
Peak displacement [deg] 0.89 0.74–1.08 0.24
Peak velocity [deg/s] 1.00 0.98–1.02 0.99
CI — confidence interval; LVEDVI — left ventricular end-diastolic volume index; LVEF — left ventricular ejection fraction; LVMVI — left  
ventricular mass/volume index; NYHA — New York Heart Association; RVEDVI — right ventricular end-diastolic volume index; RVEF — right 
ventricular ejection fraction; STS — Society of Thoracic Surgeons
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Limitations of the study
In this study, patients with severe AS were 
compared to healthy controls. Since AS is pro-
moted by well-known risk factors like arterial 
hypertension and hyperlipoproteinemia that also 
might cause other cardiac morbidities (e.g. coro-
nary artery disease), it is difficult to control for 
confounding systemic or cardiac conditions that 
might influence cardiac deformation parameters 
independently from an existing severe AS. 
There is no consensus to date on how to 
assess and report strain parameters. Therefore, 
values reported in this study are to a large extent 
modality and software specific. Comparability 
between different vendors, imaging modalities 
and post-processing software needs to be further 
evaluated and proven.
Conclusions
Assessment of left ventricular deformation 
parameters by CMR revealed subtle functional 
abnormalities in comparison to healthy controls. 
Prognostic significance remains to be further 
investigated. 
Conflict of interest: None declared
References
1. Coffey S, Cairns BJ, Iung B. The modern epidemiology of 
heart valve disease. Heart. 2016; 102(1): 75–85, doi:  10.1136/
heartjnl-2014-307020, indexed in Pubmed: 26541169.
2. Vahanian A, Alfieri O, Andreotti F, et al. ESC Committee for 
Practice Guidelines (CPG), Joint Task Force on the Management 
of Valvular Heart Disease of the European Society of Cardiol-
ogy (ESC), European Association for Cardio-Thoracic Surgery 
(EACTS). Guidelines on the management of valvular heart dis-
ease (version 2012): the Joint Task Force on the Management 
of Valvular Heart Disease of the European Society of Cardiol-
ogy (ESC) and the European Association for Cardio-Thoracic 
Surgery (EACTS). Eur J Cardiothorac Surg. 2012; 42(4): S1–44, 
doi: 10.1093/ejcts/ezs455, indexed in Pubmed: 22922698.
3. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical 
Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl 
J Med. 2016; 374: 1609–1620.
4. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-
valve replacement with a self-expanding prosthesis. N Engl 
J Med. 2014; 370(19): 1790–1798, doi: 10.1056/NEJMoa1400590, 
indexed in Pubmed: 24678937.
5. Holmes DR, et al. Jr, Mack MJ, Kaul S 2012 ACCF/AATS/SCAI/
STS expert consensus document on transcatheter aortic valve 
replacement: developed in collabration with the American Heart 
Association, American Society of Echocardiography, European 
Association for Cardio-Thoracic Surgery, Heart Failure Society 
of America, Mended Hearts, Society of Cardiovascular Anes-
thesiologists, Society of Cardiovascular Computed Tomography, 
and Society for Cardiovascular Magnetic Resonance. J Thorac 
Cardiovasc Surg. 2012; 144: e29–84.
6. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and 
predictors of early and late mortality after transcatheter aortic 
valve implantation in 663 patients with severe aortic stenosis. 
Circulation. 2011; 123(3): 299–308, doi:  10.1161/CIRCULA-
TIONAHA.110.946533, indexed in Pubmed:21220731.
7. Thomas M, Schymik G, Walther T, et al. One-year outcomes of 
cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European 
Outcome (SOURCE) registry: the European registry of trans-
catheter aortic valve implantation using the Edwards SAPIEN 
valve. Circulation. 2011; 124(4): 425–433, doi:10.1161/CIRCU-
LATIONAHA.110.001545, indexed in Pubmed: 21747054.
8. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes 
after transcatheter aortic valve implantation in high-risk patients 
with severe aortic stenosis: the U.K. TAVI (United Kingdom 
Transcatheter Aortic Valve Implantation) Registry. J Am Coll 
Cardiol. 2011; 58(20): 2130–2138, doi:10.1016/j.jacc.2011.08.050, 
indexed in Pubmed: 22019110.
9. Rodés-Cabau J, Webb JG, Cheung A, et al. Long-term outcomes 
after transcatheter aortic valve implantation: insights on prog-
nostic factors and valve durability from the Canadian multi-
center experience. J Am Coll Cardiol. 2012; 60(19): 1864–1875, 
doi: 10.1016/j.jacc.2012.08.960, indexed in Pubmed:23062535.
10. Hendel RC, Patel MR, Kramer CM, et al. American College of 
Cardiology Foundation Quality Strategic Directions Committee 
Appropriateness Criteria Working Group, American College of 
Radiology, Society of Cardiovascular Computed Tomography, So-
ciety for Cardiovascular Magnetic Resonance, American Society 
of Nuclear Cardiology, North American Society for Cardiac Imag-
ing, Society for Cardiovascular Angiography and Interventions, 
Society of Interventional Radiology. ACCF/ACR/SCCT/SCMR/
ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac 
computed tomography and cardiac magnetic resonance imaging: 
a report of the American College of Cardiology Foundation Quality 
Strategic Directions Committee Appropriateness Criteria Work-
ing Group, American College of Radiology, Society of Cardiovas-
cular Computed Tomography, Society for Cardiovascular Mag-
netic Resonance, American Society of Nuclear Cardiology, North 
American Society for Cardiac Imaging, Society for Cardiovascular 
Angiography and Interventions, and Society of Interventional Ra-
diology. J Am Coll Cardiol. 2006; 48(7): 1475–1497, doi:10.1016/j.
jacc.2006.07.003, indexed in Pubmed: 17010819.
11. Zamorano JL, Bax JJ, Rademakers FE. Evaluation of Systolic 
and Diastolic LV Function. The ESC Textbook of Cardiovascular 
Imaging. Springer, New York 2010: 307–320.
12. Buckert D, Dewes P, Walcher T, et al. Intermediate-term prog-
nostic value of reversible perfusion deficit diagnosed by ad-
enosine CMR: a prospective follow-up study in a consecutive 
patient population. JACC Cardiovasc Imaging. 2013; 6(1): 56–63, 
doi: 10.1016/j.jcmg.2012.08.011, indexed in Pubmed:23328562.
13. Buckert D, Kelle S, Buss S, et al. Left ventricular ejection frac-
tion and presence of myocardial necrosis assessed by cardiac 
magnetic resonance imaging correctly risk stratify patients with 
stable coronary artery disease: a multi-center all-comers trial. 
Clin Res Cardiol. 2017; 106(3): 219–229, doi: 10.1007/s00392-
016-1042-5, indexed in Pubmed: 27738810.
14. Hombach V, Merkle N, Bernhard P, et al. Prognostic significance 
of cardiac magnetic resonance imaging: Update 2010. Cardiol J. 
2010; 17(6): 549–557, indexed in Pubmed: 21154256.
15. Claus P, Omar AM, Pedrizzetti G, et al. Tissue tracking tech-
nology for assessing cardiac mechanics: principles, normal val-
www.cardiologyjournal.org 211
Dominik Buckert et al., Prognostic value of strain after TAVR
ues, and clinical applications. JACC Cardiovasc Imaging. 2015; 
8(12): 1444–1460, doi:  10.1016/j.jcmg.2015.11.001, indexed in 
Pubmed: 26699113.
16. Pedrizzetti G, Claus P, Kilner PJ, et al. Principles of cardiovascu-
lar magnetic resonance feature tracking and echocardiographic 
speckle tracking for informed clinical use. J Cardiovasc Magn 
Reson. 2016; 18(1): 51, doi: 10.1186/s12968-016-0269-7, indexed 
in Pubmed: 27561421.
17. Pandis D, Sengupta PP, Castillo JG, et al. Assessment of longitudinal 
myocardial mechanics in patients with degenerative mitral valve 
regurgitation predicts postoperative worsening of left ventricular 
systolic function. J Am Soc Echocardiogr. 2014; 27(6): 627–638, 
doi: 10.1016/j.echo.2014.02.008, indexed in Pubmed: 24735653.
18. Reant P, Reynaud A, Pillois X, et al. Comparison of resting 
and exercise echocardiographic parameters as indicators of out-
comes in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 
2015; 28(2): 194–203, doi: 10.1016/j.echo.2014.10.001, indexed 
in Pubmed: 25459499.
19. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure 
and function in transthyretin-related versus light-chain cardiac 
amyloidosis. Circulation. 2014; 129(18): 1840–1849, doi: 10.1161/
CIRCULATIONAHA.113.006242, indexed in Pubmed: 24563469.
20. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC 
guideline for the management of patients with valvular heart 
disease: executive summary: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice 
Guidelines. J Am Coll Cardiol. 2014; 63: 2438–88.
21. Kramer CM, Barkhausen J, Flamm SD, et al. Society for Cardiovas-
cular Magnetic Resonance Board of Trustees Task Force on Stan-
dardized Protocols. Standardized cardiovascular magnetic resonance 
(CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013; 15: 
91, doi: 10.1186/1532-429X-15-91, indexed in Pubmed: 24103764.
22. Schulz-Menger J, Bluemke DA, Bremerich J, et al. Standard-
ized image interpretation and post processing in cardiovascu-
lar magnetic resonance: Society for Cardiovascular Magnetic 
Resonance (SCMR) board of trustees task force on standard-
ized post processing. J Cardiovasc Magn Reson. 2013; 15: 35, 
doi: 10.1186/1532-429X-15-35, indexed in Pubmed: 23634753.
23. Pedrizzetti G, Claus P, Kilner PJ, et al. Principles of cardiovascu-
lar magnetic resonance feature tracking and echocardiographic 
speckle tracking for informed clinical use. J Cardiovasc Magn 
Reson. 2016; 18(1): 51, doi: 10.1186/s12968-016-0269-7, indexed 
in Pubmed: 27561421.
24. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized 
endpoint definitions for transcatheter aortic valve implantation: 
the Valve Academic Research Consortium-2 consensus docu-
ment. EuroIntervention. 2012; 8(7): 782–795, doi: 10.4244/EI-
JV8I7A121, indexed in Pubmed: 23022744.
25. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition 
of myocardial infarction. Eur Heart J. 2012; 33: 2551–67.
26. Anderson RP. First publications from the Society of Thoracic 
Surgeons National Database. Ann Thorac Surg. 1994; 57(1): 6–7, 
indexed in Pubmed:8279920.
27. Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in 
European cardiac surgery: analysis of the EuroSCORE multina-
tional database of 19030 patients. Eur J Cardiothorac Surg. 1999; 
15(6): 816–22; discussion 822, indexed in Pubmed: 10431864.
28. Weidemann F, Jamal F, Sutherland GR, et al. Myocardial function 
defined by strain rate and strain during alterations in inotropic 
states and heart rate. Am J Physiol Heart Circ Physiol. 2002; 
283(2): H792–H799, doi: 10.1152/ajpheart.00025.2002, indexed 
in Pubmed: 12124229.
29. Clemmensen TS, Eiskjær H, Løgstrup BB, et al. Left ven-
tricular global longitudinal strain predicts major adverse car-
diac events and all-cause mortality in heart transplant patients. 
J Heart Lung Transplant. 2017; 36(5): 567–576, doi: 10.1016/j.
healun.2016.12.002, indexed in Pubmed:28089194.
30. Dahou A, Bartko PE, Capoulade R, et al. Usefulness of global 
left ventricular longitudinal strain for risk stratification in low 
ejection fraction, low-gradient aortic stenosis: results from the 
multicenter True or Pseudo-Severe Aortic Stenosis study. Circ 
Cardiovasc Imaging. 2015; 8(3): e002117, doi:10.1161/CIRCIM-
AGING.114.002117, indexed in Pubmed: 25681417.
31. Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibil-
ity of echocardiographic techniques for sequential assessment 
of left ventricular ejection fraction and volumes: application to 
patients undergoing cancer chemotherapy. J Am Coll Cardiol. 
2013; 61(1): 77–84, doi:  10.1016/j.jacc.2012.09.035, indexed in 
Pubmed: 23199515.
32. Macron L, Lairez O, Nahum J, et al. Impact of acoustic win-
dow on accuracy of longitudinal global strain: a comparison 
study to cardiac magnetic resonance. Eur J Echocardiogr. 2011; 
12(5): 394–399, doi:  10.1093/ejechocard/jer029, indexed in 
Pubmed: 21471046.
33. Buss SJ, Breuninger K, Lehrke S, et al. Assessment of myocar-
dial deformation with cardiac magnetic resonance strain imaging 
improves risk stratification in patients with dilated cardiomyo-
pathy. Eur Heart J Cardiovasc Imaging. 2015; 16(3): 307–315, 
doi: 10.1093/ehjci/jeu181, indexed in Pubmed: 25246506.
34. Yang LiT, Yamashita E, Nagata Y, et al. Prognostic value of 
biventricular mechanical parameters assessed using cardiac 
magnetic resonance feature-tracking analysis to predict future 
cardiac events. J Magn Reson Imaging. 2017; 45(4): 1034–1045, 
doi: 10.1002/jmri.25433, indexed in Pubmed:27531830.
35. Delgado V, Tops LF, van Bommel RJ, et al. Strain analysis in pa-
tients with severe aortic stenosis and preserved left ventricular 
ejection fraction undergoing surgical valve replacement. Eur 
Heart J. 2009; 30(24): 3037–3047, doi: 10.1093/eurheartj/ehp351, 
indexed in Pubmed: 19726436.
36. Buckert D, Cieslik M, Tibi R, et al. Longitudinal strain assessed 
by cardiac magnetic resonance correlates to hemodynamic find-
ings in patients with severe aortic stenosis and predicts positive 
remodeling after transcatheter aortic valve replacement. Clin 
Res Cardiol. 2017 [Epub ahead of print], doi:  10.1007/s00392-
017-1153-7, indexed in Pubmed: 28808772.
37. Dinh W, Nickl W, Smettan J, et al. Reduced global longitudinal 
strain in association to increased left ventricular mass in patients 
with aortic valve stenosis and normal ejection fraction: a hybrid 
study combining echocardiography and magnetic resonance im-
aging. Cardiovasc Ultrasound. 2010; 8: 29, doi:  10.1186/1476-
7120-8-29, indexed in Pubmed: 20659321.
38. Bouleti C, Himbert D, Iung B, et al. Long-term outcome af-
ter transcatheter aortic valve implantation. Heart. 2015; 
101(12): 936–942, doi:10.1136/heartjnl-2014-306694, indexed in 
Pubmed: 25655064.
39. Arnold SV, Afilalo J, Spertus JA, et al. Prediction of Poor Outcome 
After Transcatheter Aortic Valve Replacement. J Am Coll Car-
diol. 2016; 68(17): 1868–1877, doi:  10.1016/j.jacc.2016.07.762, 
indexed in Pubmed: 27765189.
40. Reardon MJ, Van Mieghem NM, Popma JJ, et al. SURTAVI In-
vestigators. Surgical or Transcatheter Aortic-Valve Replacement 
in Intermediate-Risk Patients. N Engl J Med. 2017; 376(14): 
1321–1331, doi:  10.1056/NEJMoa1700456, indexed in Pub-
med: 28304219.
212 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 2
